Publication date: Aug 08, 2019
A vaccine that targets tumor neoantigens may improve the effectiveness of nivolumab. A trial that included patients with metastatic melanoma, non-small cell lung cancer, and bladder cancer found that progression-free survival was longer than in historical controls. The vaccine also stimulated tumor-specific T cells.
___. Vaccine Increases PFS for Metastatic Tumors. 23702. 2019 Cancer Discov.
|pathway||BSID||Non-small cell lung cancer|
|disease||DOID||non-small cell lung cancer|
|disease||MESH||non-small cell lung cancer|
- Featured Review: Evidence for the benefits and harms of screening for malignant melanoma
- A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China